CA-ANOMALI
16.12.2021 11:02:04 CET | Business Wire | Press release
Anomali , the leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions, today announced that multi-decade industry veteran Justin Coker has been named Vice President and General Manager of Europe and the Middle East (EMEA). Coker takes the region’s helm during a period of explosive demand for Anomali’s leading cybersecurity solutions, which are delivering unmatched ability in precision threat detection and comprehensive response that stops immediate and future breaches and attacks.
“Anomali is building a world-class leadership team as we continue on our phenomenal growth trajectory around the world. Justin brings a powerful combination of experience and skill to ensure that our public and private sector customers and partners receive the attention needed to build efficient, high-performance security infrastructures that stop advanced breaches and the attackers targeting their enterprises,” said Ahmed Rubaie, CEO, Anomali. “We are excited to welcome Justin to the company; his commitment to the organization and regional expertise makes him the perfect leader for the job.”
Coker has spent more than 20 years in senior sales management roles at leading enterprise cybersecurity companies. He joins Anomali from IronNet Cybersecurity, where, as VP of EMEA, he built out a sales team from the ground up on its journey to its recent IPO. Prior to then, he was VP of EMEA at Skybox Security, where he grew the business from a start-up to a team of 50, along the way winning a comprehensive list of EMEA's largest organizations as customers and creating strong alliances with many of the premier partner organizations across the region. Before that, while at Symantec, he led the United Kingdom’s and Ireland's retail banking and finance enterprise sales team for five years. He has held other successful IT sales positions at AXENT Technologies, Parametric Technology, and Fujitsu. Throughout his professional career, Coker has exceeded expectations at building and scaling successful sales teams and has remained enthusiastic about delivering business value to his clients and partners.
“I am excited to be joining Anomali at such a pivotal phase of growth and innovation. I look forward to driving our deeper portfolio adoption across EMEA through the development of existing and new markets, coupled with the continued expansion of our global channel and technology partner ecosystem,” said Coker. “Anomali’s go-to-market approach in EMEA is centered around our continued passion for creating strong partnerships with our global enterprise clients and helping them capitalize upon significant business value. I look forward to fulfilling our mission to strengthen customers’ security efficacy and efficiency, fueled by our intelligence-driven detection and response solutions and world-class customer-focused team.”
Coker and his team will be furthering access to the award-winning Anomali portfolio, which includes ThreatStream, our leading threat management platform, Lens, the industry’s only Natural Language Processing (NLP) product that identifies all threats and IOCs in any web content to operationalize them across security infrastructures, and Match, our advanced global attacker detection and response solution that quickly identifies and responds to threats in real-time by automatically correlating all security telemetry data against active threat intelligence.
Twitter:
https://twitter.com/Anomali
LinkedIn:
https://www.linkedin.com/company/anomali/
Blog:
https://www.anomali.com/blog
Detect LIVE Conference:
https://www.anomali.com/detect-live
About Anomali
Anomali is the leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions. Anchored by big data management and refined by artificial intelligence and machine learning, the Anomali platform delivers proprietary capabilities that correlate an extraordinary volume of telemetry from customer-deployed security solutions with the largest repository of global intelligence, empowering security operations teams to detect threats with precision, optimize response, achieve resiliency, and stop attackers and breaches. Our Cloud-first SaaS-based solutions easily integrate into existing security tech stacks and accommodate hybrid deployments. Founded in 2013, Anomali serves public and private sector organizations, ISACs, MSSPs, and Global 1000 customers worldwide in every major industry. Leading venture firms including Google Ventures, General Catalyst, and IVP back Anomali. Learn more at www.anomali.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215006153/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
